GENE ONLINE|News &
Viral Defense 2.0: How Long-Acting Biologics and Startups are Reimagining the Flu Season
Across next-generation flu, RSV, and pneumococcal programs, 2026 respiratory trials could redefine seasonal protection and vaccine strategy. Image: Thirdman/pexels
The global respiratory disease vaccine market is entering a period of high-stakes transformation, projected to reach $68.43 billion by the end of 2026 and potentially exceeding $98 billion by 2035. This growth is fueled by a pivot away from the “booster fatigue” that characterized the early 2020s. Instead, the industry is racing toward a “one-and-done” … Viral Defense 2.0: How Long-Acting Biologics and Startups are Reimagining the Flu Season Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.
GO Prime with only $1.49 now
LATEST
AvKARE Updates Prescribing Information for Etonogestrel and Ethinyl Estradiol Vaginal Ring
2026-09-11
Disc Medicine and Silence Therapeutics Develop Polycythemia Vera Treatments to Compete With Takeda and Protagonist
2026-09-11
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
